An overview of hepatitis B prevalence, prevention, and management in the Pacific Islands and Territories

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 11, 2014, Pages 1854-1866

  Howell, Jessica ^a,b,c,d   Van Gemert, Caroline ^c   Lemoine, Maud ^a,b   Thursz, Mark ^a,b   Hellard, Margaret ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c BURNET INSTITUTE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cirrhosis; Hepatocellular carcinoma; Liver cancer; Liver disease; Melanesian; Micronesian; Pacific Islands; Polynesian; Viral hepatitis

Indexed keywords

COMPLICATION; COST OF ILLNESS; FEMALE; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; METABOLIC SYNDROME X; PACIFIC ISLANDS; PREGNANCY; PREVALENCE; RISK FACTOR; SMOKING; TRANSMISSION; VERTICAL TRANSMISSION; WORLD HEALTH ORGANIZATION;

COST OF ILLNESS; FEMALE; HEPATITIS B; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; METABOLIC SYNDROME X; PACIFIC ISLANDS; PREGNANCY; PREVALENCE; RISK FACTORS; SMOKING; WORLD HEALTH ORGANIZATION;

EID: 84912049769     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12684     Document Type: Review

References (88)

1. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57: 167-185.
2. World Health Organization. Hepatitis B vaccines. Weekly Epidemiological Record 2009; 2009: 20-405.
3. WHO. Hepatitis B. WHO [online], http://www.who.int/csr/disease/hepatitis/HepatitisB_whocdscsrlyo2002_2.pdf accessed 21st April 2014
4. Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 1996; 38 (Suppl. 2): S18-23.
5. WHO. Countries and Areas-WHO Western Pacific Region. Cited 21 Apr 2014. Available from URL: http://wpro.who.int/countries/en/
6. Andre F. Hepatitis B epidemiology in Asia, the Middle East and Africa. Vaccine 2000; 18 (Suppl. 1): S20-22.
7. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J. Gastroenterol. Hepatol. 2009; 24: -53.
8. Wong SN, Ong JP, Labio ME etal. Hepatitis B infection among adults in the Philippines: a national seroprevalence study. World J. Hepatol. 2013; 5: 214-219.
9. Andernach IE, Jutavijittum P, Samountry B etal. A high variability of mixed infections and recent recombinations of hepatitis B virus in Laos. PLoS ONE 2012; 7: e30245.
10. Jutavijittum P, Andernach IE, Yousukh A etal. Occult hepatitis B infections among blood donors in Lao PDR. Vox Sang. 2014; 106: 31-37.
11. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007; 45: 1187-1192.
12. Chan HL, Thompson A, Martinot-Peignoux M etal. Hepatitis B surface antigen quantification: why and how to use it in 2011-a core group report. J. Hepatol. 2011; 55: 1121-1131.
13. Hsu YS, Chien RN, Yeh CT etal. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522-1527.
14. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010; 52: 1232-1241.
15. Chan HL, Jia J. Chronic hepatitis B in Asia--new insights from the past decade. J. Gastroenterol. Hepatol. 2011; 26 (Suppl. 1): 131-137.
16. Lu SQ, McGhee SM, Xie X, Cheng J, Fielding R. Economic evaluation of universal newborn hepatitis B vaccination in China. Vaccine 2013; 31: 1864-1869.
17. Chen SC, Toy M, Yeh JM, Wang JD, Resch S. Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobin treatment. Pediatrics 2013; 131: e1135-1143.
18. Lee KK, Wu DB, Chow PY, Lee VW, Li H. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong. J. Gastroenterol. Hepatol. 2012; 27: 1167-1174.
19. Wu B, Li T, Chen H, Shen J. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health 2010; 13: 592-600.
20. Qiao Q, Gao W, Zhang L, Nyamdorj R, Tuomilehto J. Metabolic syndrome and cardiovascular disease. Ann. Clin. Biochem. 2007; 44 (Pt 3): 232-263.
21. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 2012; 56: 908-943.
22. Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J. Hepatol. 2005; 42: 218-224.
23. Trichopoulos D, Bamia C, Lagiou P etal. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. J. Natl Cancer Inst. 2011; 103: 1686-1695.
24. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States veterans. Am. J. Gastroenterol. 2001; 96: 2462-2467.
25. WHO. WHO Multi-Country Cooperation Strategy for the Pacific 2013-2017. Cited 21 Apr 2014. Available from URL: http://www.wpro.who.int/southpacific/who_pacific_mccs.pdf?ua=1
26. Luthria M, Dhar S. Pacific 2020 Background Paper: Framework for Growth. Cited 21 Apr 2014. http://aid.dfat.gov.au/Publications/Documents/background_growth.pdf
27. Norder H, Courouce AM, Coursaget P etal. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004; 47: 289-309.
28. Srivatanakul P, Sriplung H, Deerasamee S. Epidemiology of liver cancer: an overview. Asian Pac. J. Cancer Prev. 2004; 5: 118-125.
29. Country cooperation strategy at a glance: Pacific Island Countries. Geneva, World Health Organization, 2011. Cited 21 Apr 2014. http://www.who.int/countryfocus/cooperation_strategy/ccsbrief_pci_en.pdf
30. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30: 2212-2219.
31. WHO. Countries and Areas-WHO Western Pacific Region. Cited 21 Apr 2014. http://www.wpro.who.int/en/
32. Wilson N, Ruff TA, Rana BJ, Leydon J, Locarnini S. The effectiveness of the infant hepatitis B immunisation program in Fiji, Kiribati, Tonga and Vanuatu. Vaccine 2000; 18: 3059-3066.
33. Bialek SR, Helgenberger L, Fischer GE etal. Impact of routine hepatitis B immunization on the prevalence of chronic hepatitis B virus infection in the Marshall Islands and the Federated States of Micronesia. Pediatr. Infect. Dis. J. 2010; 29: 18-22.
34. Bauduceau O, Berlioz A, Buisson Y. [Hepatitis B, C, and E in New Caledonia. Seroepidemiologic study in military recruits]. Med. Trop. (Mars) 2000; 60: 167-170.
35. Menard D. [Toxoplasmosis, rubella, syphilis, hepatitis B and HIV infection in women being followed for pregnancy in a population on the east coast of New Caledonia]. Bull. Soc. Pathol. Exot. 2001; 94: 403-405.
36. Vogt TM, Goldstein ST, Kuartei S. Endemic hepatitis B virus infection and chronic liver disease mortality in the Republic of Palau, 1990-2002. Trans. R. Soc. Trop. Med. Hyg. 2006; 100: 1130-1134.
37. Tozer RA. Papua New Guinea Red Cross Blood Transfusion Service: present status and future considerations. P. N. G. Med. J. 1996; 39: 38-42.
38. Furusyo N, Hayashi J, Kakuda K etal. Markedly high seroprevalence of hepatitis B virus infection in comparison to hepatitis C virus and human T lymphotropic virus type-1 infections in selected Solomon Islands populations. Am. J. Trop. Med. Hyg. 1999; 61: 85-91.
39. Lucas RE, Faoagali JL. The serological status of Solomon Island blood donors. Southeast Asian J. Trop. Med. Public Health 1999; 30: 542-545.
40. Milne A, Rodgers E, Hopkirk N. Hepatitis B vaccination of babies in Melanesia. Lancet 1995; 346: 318.
41. Danielsson N, Fakakovikaetau T, Szegedi E. Improved immunization practices reduce childhood hepatitis B infection in Tonga. Vaccine 2009; 27: 4462-4467.
42. Moulia-Pelat JP, Spiegel A, Excler JL etal. [Control of hepatitis B in French Polynesia with a program of systematic vaccination of newborns with the Genhevac B vaccine]. Sante 1996; 6: 11-15.
43. Katoanga SF. Teenage pregnancies in the Pacific: a Tongan's perspective. Cited 21 Apr 2014. http://www.pacifichealthdialog.org.fj/Volume%204/No1%20Medical%20Education%20and%20Health%20Reform/Viewpoints%20and%20Perspectives/Teenage%20pregnancies%20in%20the%20Pacific%20a%20Tongan's%20perspective.pdf
44. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am. J. Epidemiol. 1977; 105: 94-98.
45. Xu ZY, Liu CB, Francis DP etal. Prevention of perinatal acquisition of hepatitis B virus carriage using vaccine: preliminary report of a randomized, double-blind placebo-controlled and comparative trial. Pediatrics 1985; 76: 713-718.
46. Basuni AA, Butterworth L, Cooksley G, Locarnini S, Carman WF. Prevalence of HBsAg mutants and impact of hepatitis B infant immunisation in four Pacific Island countries. Vaccine 2004; 22: 2791-2799.
47. Shimakawa Y, Yan HJ, Tsuchiya N, Bottomley C, Hall AJ. Association of early age at establishment of chronic hepatitis B infection with persistent viral replication, liver cirrhosis and hepatocellular carcinoma: a systematic review. PLoS ONE 2013; 8: e69430.
48. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann. Intern. Med. 2001; 135: 759-768.
49. Utsumi T, Yano Y, Truong BX etal. Molecular epidemiological study of hepatitis B virus infection in two different ethnic populations from the Solomon Islands. J. Med. Virol. 2007; 79: 229-235.
50. Furusyo N, Kubo N, Nakashima H, Kashiwagi K, Hayashi J. Relationship of genotype rather than race to hepatitis B virus pathogenicity: a study of Japanese and Solomon Islanders. Am. J. Trop. Med. Hyg. 2004; 70: 571-575.
51. Carman WF, Van Deursen FJ, Mimms LT etal. The prevalence of surface antigen variants of hepatitis B virus in Papua New Guinea, South Africa, and Sardinia. Hepatology 1997; 26: 1658-1666.
52. Zhuang H, Coulepis AG, Zimmet P etal. Seroepidemiology of infection with hepatitis B virus in Fiji. Am. J. Epidemiol. 1982; 116: 608-616.
53. Utsumi T, Yano Y, Truong BX, Kawabata M, Hayashi Y. Characteristics of occult hepatitis B virus infection in the Solomon Islands. Int. J. Mol. Med. 2011; 27: 829-834.
54. Abbott W, Gane E, Winship I, Munn S, Tukuitonga C. Polymorphism in intron 1 of the interferon-gamma gene influences both serum immunoglobulin E levels and the risk for chronic hepatitis B virus infection in Polynesians. Immunogenetics 2007; 59: 187-195.
55. Murthy DP, SenGupta SK, Thurley JL, Cooke RA. Liver disease in Papua New Guinea 1981 to 1988, twenty years after the first surveys were done. P. N. G. Med. J. 1995; 38: 6-15.
56. Mendy ME, Welzel T, Lesi OA etal. Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa. J. Viral Hepat. 2010; 17: 115-122.
57. de Martel C, Ferlay J, Franceschi S etal. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012; 13: 607-615.
58. Olver I, Marine F, Grogan P. Disparities in cancer care in Australia and the Pacific. Oncologist 2011; 16: 930-934.
59. Moore MA, Baumann F, Foliaki S etal. Cancer epidemiology in the Pacific Islands-past, present and future. Asian Pac. J. Cancer Prev. 2010; 11 (Suppl. 2): 99-106.
60. Centre for Public Health Research. Tonga's Health 2006. Tonga: Tonga Ministry of Health, 2006
61. Haddock RL, Paulino YC, Bordallo R. Viral hepatitis and liver cancer on the Island of Guam. Asian Pac. J. Cancer Prev. 2013; 14: 3175-3176.
62. Harrison GL, Pryor J, Malani J etal. Infection frequency of hepatitis C virus and IL28B haplotypes in Papua New Guinea, Fiji, and Kiribati. PLoS ONE 2013; 8: e66749.
63. Secretariat of the Pacific Community. HIV Surveillance in Pacific Island Countries and Territories: 2012 Report. New Caledonia: Surveillance and Operational Health Research Team, Secretariat of the Pacific Community; 2013.
64. WHO. Countries and Areas-WHO Western Pacific Region. Cited 21 Apr 2014. http://www.wpro.who.int/countries/
65. Country cooperation strategy at a glance: Pacific Island Countries. Geneva, World Health Organization, 2011. Cited 21 Apr 2014. http://www.who.int/countryfocus/cooperation_strategy/ccsbrief_pci_en.pdf
66. Rasanathan K, Tukuitonga CF. Tobacco smoking prevalence in Pacific Island countries and territories: a review. N. Z. Med. J. 2007; 120: U2742.
67. Puamau ES, Roberts G, Schmich L, Power R. Drug and Alcohol Use in Fiji. Cited 21 Apr 2014. http://pacifichealthdialog.org.fj/volume/Drug%20and%20Alcohol%20Use%20in%20Fiji.pdf
68. Aggarwal R, Ghoshal UC, Naik SR. Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. J. Hepatol. 2003; 38: 215-222.
69. Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, Chen DS. Minimization of hepatitis B infection by a 25-year universal vaccination program. J. Hepatol. 2012; 57: 730-735.
70. Marion SA, Tomm Pastore M, Pi DW, Mathias RG. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. Am. J. Epidemiol. 1994; 140: 734-746.
71. Lehmann D, Vail J, Firth MJ, de Klerk NH, Alpers MP. Benefits of routine immunizations on childhood survival in Tari, Southern Highlands Province, Papua New Guinea. Int. J. Epidemiol. 2005; 34: 138-148.
72. Moulia-Pelat JP, Spiegel A, Martin PM etal. A 5-year immunization field trial against hepatitis B using a Chinese hamster ovary cell recombinant vaccine in French Polynesian newborns: results at 3 years. Vaccine 1994; 12: 499-502.
73. Hepatitis B vaccines. Wkly. Epidemiol. Rec. 2004; 79: 255-263.
74. MacIntyre CR. Hepatitis B vaccine: risks and benefits of universal neonatal vaccination. J. Paediatr. Child Health 2001; 37: 215-217.
75. Poovorawan Y, Chongsrisawat V, Theamboonlers A etal. Long-term benefit of hepatitis B vaccination among children in Thailand with transient hepatitis B virus infection who were born to hepatitis B surface antigen-positive mothers. J. Infect. Dis. 2009; 200: 33-38.
76. Thursz M, Njie R, Lemoine M. Hepatitis: global eradication of hepatitis B-feasible or fallacy? Nat. Rev. Gastroenterol. Hepatol. 2012; 9: 492-494.
77. Pan CQ, Mi LJ, Bunchorntavakul C etal. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig. Dis. Sci. 2012; 57: 2423-2429.
78. Berlioz-Arthaud A, Perolat P, Buisson Y. 10 year assessment of infant hepatitis B vaccination program, in the Loyalty Islands (New Caledonia). Vaccine 2003; 21: 2737-2742.
79. Global policy report on the prevention and control of viral hepatitis. Cited 21 Apr 2014. http://www.who.int/csr/disease/hepatitis/global_report/en/
80. Downing SG, Lagani W, Guy R, Hellard M. Barriers to the delivery of the hepatitis B birth dose: a study of five Papua New Guinean hospitals in 2007. P. N. G. Med. J. 2008; 51: 47-55.
81. Pan CQ, Duan ZP, Bhamidimarri KR etal. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin. Gastroenterol. Hepatol. 2012; 10: 452-459.
82. Borresen ML, Koch A, Biggar RJ etal. Effectiveness of the targeted hepatitis B vaccination program in Greenland. Am. J. Public Health 2012; 102: 277-284.
83. Xu H, Zeng T, Liu JY etal. Measures to reduce mother-to-child transmission of hepatitis B virus in China: a meta-analysis. Dig. Dis. Sci. 2014; 59: 242-258.
84. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 2006; 332: 328-336.
85. Han L, Zhang HW, Xie JX, Zhang Q, Wang HY, Cao GW. A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J. Gastroenterol. 2011; 17: 4321-4333.
86. Nurutdinova D, Onen NF, Hayes E, Mondy K, Overton ET. Adverse effects of tenofovir use in HIV-infected pregnant women and their infants. Ann. Pharmacother. 2008; 42: 1581-1585.
87. WHO. WHO Country Cooperation Strategy: Papua New Guinea 2010-2015. Cited 21 Apr 2014. http://www.wpro.who.int/countries/png/ccs_png_en.pdf
88. Lemoine M, Thursz M, Njie R, Dusheiko G. Forgotten, not neglected: viral hepatitis in resource-limited settings, recall for action. Liver Int. 2014; 34: 12-15.